Detalhe da pesquisa
1.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37870976
2.
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Oncologist
; 26(11): 925-e1918, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34288257
3.
Results of Lung Cancer Screening in the Community.
Ann Fam Med
; 18(3): 243-249, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32393560
4.
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Cancer
; 123(2): 303-311, 2017 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27583688
5.
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
Invest New Drugs
; 35(5): 608-615, 2017 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28204981
6.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Lancet Oncol
; 17(3): 299-308, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26858122
7.
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape.
NPJ Precis Oncol
; 8(1): 90, 2024 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38627602
8.
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
JTO Clin Res Rep
; 5(2): 100619, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38328473
9.
Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments.
Front Oncol
; 13: 1241402, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38273845
10.
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
Clin Cancer Res
; 29(12): 2173-2175, 2023 06 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37040070
11.
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Lung Cancer
; 178: 166-171, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36868177
12.
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
J Clin Oncol
; 41(15): 2724-2735, 2023 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36780608
13.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Nat Med
; 29(10): 2577-2585, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37710001
14.
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer.
Am Soc Clin Oncol Educ Book
; 42: 1-14, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35671433
15.
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.
J Med Econ
; 25(1): 108-118, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34927520
16.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
J Immunother Cancer
; 10(8)2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35940825
17.
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Clin Cancer Res
; 28(10): 2020-2029, 2022 05 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35165101
18.
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Clin Cancer Res
; 27(16): 4521-4530, 2021 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34083236
19.
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
J Immunother Cancer
; 9(7)2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34301808
20.
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
J Thorac Oncol
; 16(4): 653-664, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33333328